KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments (2016 - 2023)

Esperion Therapeutics filings provide 5 years of Change in Acquisitions & Divestments readings, the most recent being $17.5 million for Q2 2023.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 250.0% to $17.5 million in Q2 2023 year-over-year; TTM through Mar 2024 was $17.5 million, a 81.18% decrease, with the full-year FY2023 number at $42.5 million, down 37.5% from a year prior.
  • Change in Acquisitions & Divestments hit $17.5 million in Q2 2023 for Esperion Therapeutics, down from $25.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $45.9 million in Q1 2019 to a low of $2.2 million in Q3 2020.
  • Median Change in Acquisitions & Divestments over the past 4 years was $23.3 million (2019), compared with a mean of $20.8 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: plummeted 89.62% in 2020 and later soared 250.0% in 2023.
  • Esperion Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2019, then plummeted by 55.0% to $2.2 million in 2020, then skyrocketed by 1233.38% to $30.0 million in 2022, then plummeted by 41.67% to $17.5 million in 2023.
  • The last three reported values for Change in Acquisitions & Divestments were $17.5 million (Q2 2023), $25.0 million (Q1 2023), and $30.0 million (Q4 2022) per Business Quant data.